-
Deferoxamine (DeferoxamineB): Iron Chelator for Oncology Res
2026-05-30
Deferoxamine (DeferoxamineB) is a validated iron chelator with potent antiproliferative, apoptosis-inducing, and autophagy-modulating effects. Its molecular action underpins key advances in regulated cell death research and metabolic intervention strategies for cancer. The compound's solubility, storage, and usage parameters are well-established, supporting reproducibility in biomedical workflows.
-
METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC
2026-05-29
Wang et al. uncover a novel METTL16-SENP3-LTF signaling axis that confers resistance to ferroptosis and promotes tumor development in hepatocellular carcinoma. Their mechanistic findings link RNA methylation with iron metabolism, offering new targets for sensitizing HCC to ferroptosis-based therapies.
-
GMDS Drives Core Fucosylation in MYCN-Amplified Neuroblastom
2026-05-29
This study identifies GDP-mannose 4,6-dehydratase (GMDS) as a crucial regulator of core fucosylation and tumorigenesis in MYCN-amplified neuroblastoma. By linking N-MYC–mediated transcriptional control of GMDS to aggressive tumor behavior, the findings reveal a metabolic vulnerability that could inform targeted therapies.
-
Ruxolitinib Phosphate Induces Apoptosis and Pyroptosis in AT
2026-05-28
This study uncovers that ruxolitinib phosphate (INCB018424) triggers both apoptosis and GSDME-dependent pyroptosis in anaplastic thyroid carcinoma (ATC) by inhibiting DRP1-mediated mitochondrial fission via JAK1/2-STAT3 pathway suppression. These findings highlight a novel mechanism of action for JAK/STAT pathway modulation in aggressive thyroid cancers with limited therapeutic options.
-
Mubritinib (TAK 165): Optimizing Complex I Inhibition in Can
2026-05-28
Mubritinib (TAK 165) enables precise, targeted inhibition of mitochondrial electron transport chain complex I, selectively inducing cytotoxicity in chemotherapy-resistant AML and KSHV-positive lymphoma models. This guide details advanced workflows, troubleshooting strategies, and protocol enhancements to maximize the translational value of Mubritinib in cancer biology and HER2-driven research.
-
Acifran: Structural Precision in Lipid Metabolism Research
2026-05-27
Acifran, a selective HM74A/GPR109A and GPR109B agonist, is reshaping lipid metabolism research through mechanistic clarity and validated receptor targeting. This article offers translational researchers strategic guidance, blending new structural insights, workflow best practices, and a forward-looking vision for metabolic disorder studies. By anchoring discussion in high-resolution cryo-EM findings and practical laboratory integration, we demonstrate how Acifran advances the field beyond conventional compound listings.
-
Dacarbazine: Precision Workflows for Antineoplastic Chemothe
2026-05-27
Unlock the full potential of Dacarbazine through optimized in vitro and translational protocols, leveraging its alkylating power for malignant melanoma, Hodgkin lymphoma, and sarcoma research. This guide bridges bench-proven workflows with troubleshooting insights, translating recent systems biology innovations into actionable lab strategies.
-
Rotavirus Drives Nrf2 Pathway Suppression via Proteasomal De
2026-05-26
This study reveals that progressive rotavirus infection sharply downregulates the redox-sensitive transcription factor Nrf2 and its downstream antioxidant genes via enhanced proteasomal degradation, independent of classical redox or turnover pathways. These findings reshape our understanding of viral manipulation of host antioxidant defenses and offer mechanistic insight for redox enzyme function probes in antiviral and oxidative stress research.
-
7-Ethyl-10-hydroxycamptothecin: Applied Workflows in Colon C
2026-05-26
7-Ethyl-10-hydroxycamptothecin is a dual-mechanism agent, combining potent topoisomerase I inhibition with oncoprotein FUBP1 pathway disruption, redefining advanced colon cancer research. This article delivers actionable experimental protocols, troubleshooting strategies, and evidence-backed insights to maximize reproducibility and mechanistic depth in apoptosis and cell cycle studies.
-
Magnetic Bispecific Nano-Antibodies Enable In Vivo CAR-T Mim
2026-05-25
This study introduces a magnetic bispecific nano-antibody (M-BiNanoAb) platform for in vivo generation and navigation of CAR-T-mimicking cells to target solid tumors. The approach addresses longstanding barriers in CAR-T therapy for solid tumors by enabling direct T cell programming and magnetically guided tumor infiltration, with promising implications for next-generation immunotherapy.
-
Lipid Nanoparticle Delivery of ABE8e Corrects COL7A1 Mutatio
2026-05-25
The referenced study demonstrates efficient lipid nanoparticle (LNP) delivery of the adenine base editor ABE8e to correct COL7A1 mutations in fibroblasts from dystrophic epidermolysis bullosa (DEB) patients in vitro. This work highlights LNPs as a non-viral, precise means for gene correction, paving the way for potential genetic therapies targeting inherited skin disorders.
-
MLN4924: Precision NEDD8-Activating Enzyme Inhibition in Can
2026-05-24
MLN4924 offers researchers a highly selective tool for dissecting neddylation pathway dynamics and cullin-RING ligase ubiquitination inhibition, enabling the exploration of protein degradation in cancer models. Its robust performance in xenograft studies and practical solubility profile set it apart for both mechanistic and translational workflows.
-
Phosphoproteomic Remodeling in RCC Under Chronic Cabozantini
2026-05-23
This study applies quantitative phosphoproteomics to dissect how renal cell carcinoma (RCC) cells adapt to acute versus chronic Cabozantinib (XL184) exposure. The findings reveal distinct timescale-dependent remodeling of phosphorylation networks, particularly in adhesion and MAPK-associated pathways, informing future research into resistance mechanisms and therapeutic strategies.
-
JC-1 Fluorescent Probe: Optimizing Mitochondrial Membrane Po
2026-05-22
JC-1 enables highly sensitive, ratiometric detection of mitochondrial membrane potential for apoptosis and bioenergetics studies. This guide delivers advanced protocols, troubleshooting tactics, and practical insights that maximize the assay’s reproducibility, drawing from cutting-edge reference studies and the robust performance of APExBIO’s high-purity JC-1.
-
BKT140 (BL-8040) CXCR4 Antagonist: Applied Oncology Workflow
2026-05-22
BKT140 (BL-8040) empowers oncology researchers with high-fidelity CXCR4-mediated chemotaxis inhibition and potent stem cell mobilization, enabling precise modeling of tumor progression and therapeutic response. This guide distills the latest theranostic principles and protocol optimizations, equipping labs to troubleshoot and extend their cancer biology workflows with confidence.